Fulcrum Therapeutics Inc. (FULC)
NASDAQ (NMS) NASDAQ (NMS) Primary 
FMR LLC's Strategic Reduction in Fulcrum Therapeutics Inc Shares
On September 30, 2024, FMR LLC (Trades, Portfolio) executed a significant transaction involving the sale of 3,605,932 shares in Fulcrum Therapeutics Inc (FULC, Financial), a clinical-stage biopharmaceutical company. This move reduced FMR LLC (Trades, Portfolio)'s holdings in the company to 1,724,014 shares, marking a notable shift in its investment strategy.
Shareholder Rights Advocates at Levi & Korsinsky Investigate Fulcrum Therapeutics, Inc. (FULC) Regarding Possible Securities Fraud Violations
NEW YORK, NY / ACCESSWIRE / October 7, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics, Inc.") (NASDAQ:FULC) concerning possible violations of federal securities laws. Fulcrum announced on September 12, 2024, that "its Phase 3 REACH trial evaluating losmapimod in patients with FSHD, did not achieve its primary endpoint of change from baseline in RSA with losmapimod compared to placebo.
Down -57.53% in 4 Weeks, Here's Why Fulcrum Therapeutics (FULC) Looks Ripe for a Turnaround
Fulcrum Therapeutics (FULC) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Investors Are Invited To Join The Schall Law Firm In An Inquiry Into Fulcrum Therapeutics Inc For Possible Securities Fraud
LOS ANGELES, CA / ACCESSWIRE / October 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Fulcrum Therapeutics, Inc. ("Fulcrum" or "the Company") (NASDAQ:FULC) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Fulcrum Therapeutics, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights – FULC
NEW YORK, NY / ACCESSWIRE / October 1, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics, Inc.") (NASDAQ:FULC) concerning possible violations of federal securities laws. Fulcrum announced on September 12, 2024, that "its Phase 3 REACH trial evaluating losmapimod in patients with FSHD, did not achieve its primary endpoint of change from baseline in RSA with losmapimod compared to placebo.
Fulcrum Therapeutics, Inc. Is Being Investigated For Violating Securities Laws And The Schall Law Firm Urges Shareholder Participation
LOS ANGELES, CA / ACCESSWIRE / October 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Fulcrum Therapeutics, Inc. ("Fulcrum" or "the Company") (NASDAQ:FULC) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Fulcrum Therapeutics, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Fulcrum Therapeutics, Inc. (FULC)
NEW YORK, NY / ACCESSWIRE / September 30, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics, Inc.") (NASDAQ:FULC) concerning possible violations of federal securities laws. Fulcrum announced on September 12, 2024, that "its Phase 3 REACH trial evaluating losmapimod in patients with FSHD, did not achieve its primary endpoint of change from baseline in RSA with losmapimod compared to placebo.
Investors Are Encouraged To Join The Schall Law Firm In An Inquiry Into Fulcrum Therapeutics Inc For Possible Securities Fraud
LOS ANGELES, CA / ACCESSWIRE / September 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Fulcrum Therapeutics, Inc. ("Fulcrum" or "the Company") (NASDAQ:FULC) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Levi & Korsinsky Reminds Fulcrum Therapeutics, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities Laws - FULC
NEW YORK, NY / ACCESSWIRE / September 29, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics, Inc.") (NASDAQ:FULC) concerning possible violations of federal securities laws. Fulcrum announced on September 12, 2024, that "its Phase 3 REACH trial evaluating losmapimod in patients with FSHD, did not achieve its primary endpoint of change from baseline in RSA with losmapimod compared to placebo.
Fulcrum Therapeutics, Inc. Is Being Investigated For Securities Law Violations And The Schall Law Firm Invites Shareholders With Losses To Help
LOS ANGELES, CA / ACCESSWIRE / September 29, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Fulcrum Therapeutics, Inc. ("Fulcrum" or "the Company") (NASDAQ:FULC) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Levi & Korsinsky Announces an Investigation on Behalf of Fulcrum Therapeutics, Inc. (FULC) Shareholders Who May Have Been Affected by Fraud
NEW YORK, NY / ACCESSWIRE / September 28, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics, Inc.") (NASDAQ:FULC) concerning possible violations of federal securities laws. Fulcrum announced on September 12, 2024, that "its Phase 3 REACH trial evaluating losmapimod in patients with FSHD, did not achieve its primary endpoint of change from baseline in RSA with losmapimod compared to placebo.
The Schall Law Firm Is Looking Into Whether Fulcrum Therapeutics Inc Committed Securities Fraud And Impacted Investors Should Reach Out
LOS ANGELES, CA / ACCESSWIRE / September 28, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Fulcrum Therapeutics, Inc. ("Fulcrum" or "the Company") (NASDAQ:FULC) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
